LGND

Zacks Small Cap Research – LGND: 2025 View Calls for 17% Topline Growth – Go Health Pro

by
Zacks Small Cap Research – LGND: 2025 View Calls for 17% Topline Growth – Go Health Pro

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its annual analyst day on December 10th, 2024 in Boston. The company provided its 2025 expectations calling for topline revenues of $180 to $200 million and core adjusted earnings per share (EPS) of $6.00 to $6.25. This represents an … Read more

Zacks Small Cap Research – LGND: Initiating Coverage – A Prince Among Royalty – Go Health Pro

by
Zacks Small Cap Research – LGND: Initiating Coverage – A Prince Among Royalty – Go Health Pro

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreciation and amortization (EBITDA) and earnings estimates. Ligand is a biopharmaceutical royalty … Read more

x